-
摘要:
目的 探讨乳腺癌患者肿瘤组织中凋亡抑制基因AVEN mRNA的表达情况, 分析其在临床诊治中的意义。 方法 采用SYBR®Green实时荧光定量PCR方法, 检测在89例乳腺癌患者癌组织和癌旁组织中的AVEN mRNA表达。AVEN mRNA的表达与临床病理学和危险因素的关系采用t检验和单因素方差分析。 结果 AVEN mRNA的表达在服用避孕药的患者中明显低于未服用避孕药的乳腺癌患者(P=0.02), 而与肿瘤大小、淋巴结转移、临床分期、ER、PR等临床特征无关(P > 0.05), 与患者的年龄、BMI指数、怀孕次数、是否绝经、月经初潮年龄、是否母乳喂养、累积行经年数、初产前行经年数等危险因素亦无关(P > 0.05)。 结论 口服避孕药与乳腺癌患者肿瘤AVEN mRNA的表达呈负相关。 Abstract:Objective This work aims to investigate the AVEN mRNA level of breast cancer and analyze its clinical significance in the treatment of breast cancer. Methods SYBR® Green real-time quantitative polymerase chain reaction was used to determine AVEN mRNA expression in 89 breast carcinoma and para-carcinoma tissue samples.SPSS 16.0 software was employed for statistical analysis of the data.The relationship of AVEN mRNA expression with all of the clinicopathologic characteristics and risk factors was evaluated using the t test and ANOVA.The odds ratio values and their confidence intervals were calculated(95%CI).P < 0.05 was considered statistically significant. Results The AVEN mRNA level was significantly lower in the breast cancer patients who took contraceptives than in those who did not(P=0.02).The level had no correlation with tumor size, lymph node metastasis, clinical stage, estrogen receptors, progesterone receptors, and other clinical features(P > 0.05).Furthermore, level had no relationship with the patient's age, BMI index, number of pregnancies, menopause status, menarche age, and breastfeeding, as well as risk factors such as the number of years of cumulative menstruations and the years of prenatal menstruation before primiparity(P > 0.05). Conclusion Oral contraceptives are related to the low expression of apoptosis inhibitor gene AVEN in breast tumor tissue. -
Key words:
- Breast cancer /
- Apoptosis /
- mRNA
-
表 1 不同临床病理特征乳腺癌患者的AVEN mRNA的表达水平
Table 1. AVEN mRNA expression levels in breast cancer patients with different clinical characteristics
表 2 不同影响因素与乳腺癌患者的AVEN mRNA的表达水平的关系 （%）
Table 2. AVEN mRNA expression levels in breast cancer patients with different risk factors
-
[1] Chau BN, Cheng EH, Kerr DA, et al. Aven, a novel inhibitor of caspase activadon, binds Bcl-xL and Apaf-1[J]. Mol Cell, 2000, 6 (1): 31-40. doi: 10.1016/S1097-2765(05)00021-3 [2] Cheng EH, Levine B, Boise LH, et al. Bax-independent inhibition of apoptosis by Bcl-XL[J]. Nature, 1996, 379(6565): 554-556. doi: 10.1038/379554a0 [3] 李昆, 李世正, 张蕴莉, 等. 槲皮素对人乳腺癌细胞MDA-MB-435S增殖及侵袭力的影响[J]. 肿瘤防治研究, 2009(7): 549-551. doi: 10.3971/j.issn.1000-8578.2009.07.003 [4] Nivitchanyong T, Martinez A, Ishaque A, et al. Anti-apoptotic genes Aven and E1B-19K enhance performance of BHK cells engineered to express recombinant factor Ⅷ in batch and low perfusion cell culture[J]. Biotechnol Bioeng, 2007, 98(4): 825-841. doi: 10.1002/bit.21479 [5] Guo J Y, Yamada A, Kajino T, et al. Aven-dependent activation of ATM following DNA damage[J]. Curr Biol, 2008, 18(13): 933-942. doi: 10.1016/j.cub.2008.05.045 [6] Figueroa BJ, Chen S, Oyler GA, et al. Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions[J]. Biotechnol Bioeng, 2004, 85(6): 589-600. doi: 10.1002/bit.10913 [7] Martin LJ, Liu Z, Chen K, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death[J]. J Comp Neurol, 2007, 500(1): 20-46. doi: 10.1002/cne.21160 [8] Gross A. A new Aven-ue to DNA-damage checkpoints[J]. Trends Biochem Sci, 2008, 33(11): 514-516. doi: 10.1016/j.tibs.2008.08.005 [9] Wang W, John EM, Ingles SA. Androgen receptor and prostate -specific antigen gene polymorphisms and breast cancer in African -American women[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(12): 2990-2994. doi: 10.1158/1055-9965.EPI-05-0310 [10] Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature[J]. Cancer Epidemiol Biomarkers Prev, 2004, 13(10): 1558-1568. [11] Spurdle AB, Antoniou AC, Duffy DL, et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers[J]. Breast Cancer Res, 2005, 7(2): R176-R183. doi: 10.1186/bcr971 [12] Sugarbaker DJ, Richards WG, Gordon GJ, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors[J]. Proc Nad Acad Sci U S A, 2008, 105(9): 3521-3526. doi: 10.1073/pnas.0712399105 [13] Doria H, Kyung YS, Ellis D, et al. Expression of anti-apoptosis genes alters lactate metabolism of Chinese Hamster Ovary cells in culture[J]. Biotechnol Bioeng, 2009, 103(3): 592-608. doi: 10.1002/bit.22269 -
点击查看大图
表(2)
计量
- 文章访问数: 39
- HTML全文浏览量: 17
- PDF下载量: 0
- 被引次数: 0
下载:
